Tioga Pharma D-IBS drug gets FDA fast track status
The company is organizing a multi-center Phase 3 trial investigating asimadoline in D-IBS, conducted under a Special Protocol Assessment agreement with the FDA for US registration. Tioga Pharma
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).